KR101834707B1 - 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 - Google Patents
항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 Download PDFInfo
- Publication number
- KR101834707B1 KR101834707B1 KR1020177008719A KR20177008719A KR101834707B1 KR 101834707 B1 KR101834707 B1 KR 101834707B1 KR 1020177008719 A KR1020177008719 A KR 1020177008719A KR 20177008719 A KR20177008719 A KR 20177008719A KR 101834707 B1 KR101834707 B1 KR 101834707B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- compound
- formula
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCCCCCCC1C(C(CC)CN)([C@@](C)C(C)C)C1C(C*)CCCCC Chemical compound CCCCCCCC1C(C(CC)CN)([C@@](C)C(C)C)C1C(C*)CCCCC 0.000 description 18
- VBDCIDRYXPFDFA-UHFFFAOYSA-N CC(C)C(C)COC(CNC)=O Chemical compound CC(C)C(C)COC(CNC)=O VBDCIDRYXPFDFA-UHFFFAOYSA-N 0.000 description 1
- YRJZXBJXYOBRLR-UHFFFAOYSA-N CC(C)OC(CNC)=O Chemical compound CC(C)OC(CNC)=O YRJZXBJXYOBRLR-UHFFFAOYSA-N 0.000 description 1
- CMJHOCVFHDFHFR-UNAUFEGUSA-N CC12C(SC)=NC=NC1=C(C(C1(C)[O-]Cc3ccccc3)(O)O[C@H](COCc3ccccc3)[C@H]1OCc1ccccc1)SC2 Chemical compound CC12C(SC)=NC=NC1=C(C(C1(C)[O-]Cc3ccccc3)(O)O[C@H](COCc3ccccc3)[C@H]1OCc1ccccc1)SC2 CMJHOCVFHDFHFR-UNAUFEGUSA-N 0.000 description 1
- HVNPFQOMBNYVMB-UHFFFAOYSA-N CCCCOC(CNC)=O Chemical compound CCCCOC(CNC)=O HVNPFQOMBNYVMB-UHFFFAOYSA-N 0.000 description 1
- IAWXPNFVJNMDHF-HIHHBDSQSA-N CSc1ncnc2c(C([C@@H]3OCc4ccccc4)(O)O[C@H](COCc4ccccc4)[C@H]3OCc3ccccc3)[s]cc12 Chemical compound CSc1ncnc2c(C([C@@H]3OCc4ccccc4)(O)O[C@H](COCc4ccccc4)[C@H]3OCc3ccccc3)[s]cc12 IAWXPNFVJNMDHF-HIHHBDSQSA-N 0.000 description 1
- BEMCZSKGOKRKQC-RULCWPDDSA-N C[C@@]1([C@H](c([s]cc23)c2nc(N)nc3N)O[C@H](CO)[C@H]1O)O Chemical compound C[C@@]1([C@H](c([s]cc23)c2nc(N)nc3N)O[C@H](CO)[C@H]1O)O BEMCZSKGOKRKQC-RULCWPDDSA-N 0.000 description 1
- HYUBUAJSVPTGNV-NUBDZMHLSA-N C[C@@]1([C@H](c([s]cc23)c2ncnc3N)O[C@H](CO)[C@H]1O)F Chemical compound C[C@@]1([C@H](c([s]cc23)c2ncnc3N)O[C@H](CO)[C@H]1O)F HYUBUAJSVPTGNV-NUBDZMHLSA-N 0.000 description 1
- FHOZPJTWYIPANB-NUBDZMHLSA-N C[C@@]1([C@H](c([s]cc23)c2ncnc3N)O[C@H](CO)[C@H]1O)O Chemical compound C[C@@]1([C@H](c([s]cc23)c2ncnc3N)O[C@H](CO)[C@H]1O)O FHOZPJTWYIPANB-NUBDZMHLSA-N 0.000 description 1
- SULIDDYKOYAZRH-IJIWEVSFSA-N C[C@@]1([C@H](c([s]cc23)c2ncnc3N)O[C@H](COCc2ccccc2)[C@H]1OCc1ccccc1)OCc1ccccc1 Chemical compound C[C@@]1([C@H](c([s]cc23)c2ncnc3N)O[C@H](COCc2ccccc2)[C@H]1OCc1ccccc1)OCc1ccccc1 SULIDDYKOYAZRH-IJIWEVSFSA-N 0.000 description 1
- HQVJBRZWHQHVEM-PUNQOFFKSA-N C[C@](C(OC)O[C@@H]1C2C=O)([C@]12OC(c1ccc(C)cc1)=O)O Chemical compound C[C@](C(OC)O[C@@H]1C2C=O)([C@]12OC(c1ccc(C)cc1)=O)O HQVJBRZWHQHVEM-PUNQOFFKSA-N 0.000 description 1
- YOUGYCLSWGRWPO-CWAZNJFBSA-N C[C@](C(OC)O[C@@H]1C2O)([C@]12O)O Chemical compound C[C@](C(OC)O[C@@H]1C2O)([C@]12O)O YOUGYCLSWGRWPO-CWAZNJFBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15124809P | 2009-02-10 | 2009-02-10 | |
| US61/151,248 | 2009-02-10 | ||
| PCT/US2010/023586 WO2010093608A1 (en) | 2009-02-10 | 2010-02-09 | Carba-nucleoside analogs for antiviral treatment |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117020990A Division KR101724759B1 (ko) | 2009-02-10 | 2010-02-09 | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170039759A KR20170039759A (ko) | 2017-04-11 |
| KR101834707B1 true KR101834707B1 (ko) | 2018-03-05 |
Family
ID=42333309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177008719A Expired - Fee Related KR101834707B1 (ko) | 2009-02-10 | 2010-02-09 | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 |
| KR1020117020990A Expired - Fee Related KR101724759B1 (ko) | 2009-02-10 | 2010-02-09 | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117020990A Expired - Fee Related KR101724759B1 (ko) | 2009-02-10 | 2010-02-09 | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8012942B2 (enExample) |
| EP (2) | EP2396340B1 (enExample) |
| JP (2) | JP5746638B2 (enExample) |
| KR (2) | KR101834707B1 (enExample) |
| CN (1) | CN102348713B (enExample) |
| AP (1) | AP2922A (enExample) |
| AU (3) | AU2010213873B2 (enExample) |
| BR (1) | BRPI1013643A2 (enExample) |
| CA (1) | CA2751277C (enExample) |
| CL (1) | CL2011001906A1 (enExample) |
| CO (1) | CO6420354A2 (enExample) |
| DK (1) | DK2396340T3 (enExample) |
| EA (1) | EA025085B1 (enExample) |
| ES (2) | ES2453078T3 (enExample) |
| HR (1) | HRP20140219T1 (enExample) |
| IL (1) | IL214396A (enExample) |
| MX (2) | MX2011008409A (enExample) |
| NZ (1) | NZ594370A (enExample) |
| PE (3) | PE20160858A1 (enExample) |
| PL (1) | PL2396340T3 (enExample) |
| PT (2) | PT2719701T (enExample) |
| SG (1) | SG173186A1 (enExample) |
| SI (1) | SI2396340T1 (enExample) |
| SM (1) | SMT201400056B (enExample) |
| UA (2) | UA112140C2 (enExample) |
| WO (1) | WO2010093608A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| CN102046626A (zh) | 2008-04-23 | 2011-05-04 | 吉里德科学公司 | 用于抗病毒治疗的carba-核苷类似物 |
| DK2480559T3 (da) * | 2009-09-21 | 2013-08-05 | Gilead Sciences Inc | Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger |
| PH12013500033A1 (en) | 2010-07-19 | 2017-07-26 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| MA34470B1 (fr) | 2010-07-22 | 2013-08-01 | Gilead Sciences Inc | Procédés et composés pour traiter des infections à virus paramyxoviridae |
| AU2011306066B2 (en) * | 2010-09-20 | 2015-01-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013084165A1 (en) * | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| CN104470939B (zh) | 2012-05-22 | 2017-04-26 | 埃迪尼克斯医药有限责任公司 | 用于肝脏疾病的d型氨基酸化合物 |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| HK1207647A1 (en) | 2012-10-08 | 2016-02-05 | Idenix Pharmaceuticals Llc | 2'-chloro nucleoside analogs for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| WO2015127848A1 (zh) * | 2014-02-27 | 2015-09-03 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| WO2016178876A2 (en) * | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| MX394858B (es) | 2015-09-16 | 2025-03-24 | Gilead Sciences Inc | Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae |
| CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
| US20230365608A1 (en) * | 2019-02-01 | 2023-11-16 | Janssen Biopharma, Inc. | Antiviral nucleosides and derivatives thereof |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| JP7664287B2 (ja) | 2020-05-29 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | レムデシビル治療方法 |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| KR20250111239A (ko) * | 2020-08-27 | 2025-07-22 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| CN117500494A (zh) | 2021-06-17 | 2024-02-02 | 阿堤亚制药公司 | 有利的抗hcv联合疗法 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3347723B2 (ja) | 1990-06-13 | 2002-11-20 | グラツィエル，アーノルド | 含リンプロドラッグ |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| AU2001235278A1 (en) | 2000-02-18 | 2001-08-27 | Shire Biochem Inc | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| EP1411954B1 (en) | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| JP2004532184A (ja) | 2001-01-22 | 2004-10-21 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
| CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| EP3109244B1 (en) | 2004-09-14 | 2019-03-06 | Gilead Pharmasset LLC | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| EP1814561A4 (en) * | 2004-10-29 | 2012-12-19 | Biocryst Pharm Inc | THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2114980B1 (en) | 2007-01-12 | 2012-06-27 | BioCryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2155758B1 (en) | 2007-05-10 | 2012-08-22 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
-
2010
- 2010-02-09 AU AU2010213873A patent/AU2010213873B2/en not_active Ceased
- 2010-02-09 MX MX2011008409A patent/MX2011008409A/es active IP Right Grant
- 2010-02-09 ES ES10704068.5T patent/ES2453078T3/es active Active
- 2010-02-09 KR KR1020177008719A patent/KR101834707B1/ko not_active Expired - Fee Related
- 2010-02-09 KR KR1020117020990A patent/KR101724759B1/ko not_active Expired - Fee Related
- 2010-02-09 UA UAA201506736A patent/UA112140C2/uk unknown
- 2010-02-09 PT PT131946055T patent/PT2719701T/pt unknown
- 2010-02-09 AP AP2011005818A patent/AP2922A/xx active
- 2010-02-09 WO PCT/US2010/023586 patent/WO2010093608A1/en not_active Ceased
- 2010-02-09 US US12/702,957 patent/US8012942B2/en active Active
- 2010-02-09 BR BRPI1013643A patent/BRPI1013643A2/pt active Search and Examination
- 2010-02-09 DK DK10704068.5T patent/DK2396340T3/en active
- 2010-02-09 EP EP10704068.5A patent/EP2396340B1/en active Active
- 2010-02-09 NZ NZ594370A patent/NZ594370A/en not_active IP Right Cessation
- 2010-02-09 PE PE2016000758A patent/PE20160858A1/es not_active Application Discontinuation
- 2010-02-09 EP EP13194605.5A patent/EP2719701B1/en active Active
- 2010-02-09 PT PT107040685T patent/PT2396340E/pt unknown
- 2010-02-09 CN CN201080011690.0A patent/CN102348713B/zh not_active Expired - Fee Related
- 2010-02-09 SI SI201030554T patent/SI2396340T1/sl unknown
- 2010-02-09 HR HRP20140219AT patent/HRP20140219T1/hr unknown
- 2010-02-09 ES ES13194605.5T patent/ES2628842T3/es active Active
- 2010-02-09 SG SG2011054798A patent/SG173186A1/en unknown
- 2010-02-09 PE PE2016000564A patent/PE20161067A1/es not_active Application Discontinuation
- 2010-02-09 PL PL10704068T patent/PL2396340T3/pl unknown
- 2010-02-09 PE PE2011001464A patent/PE20120257A1/es active IP Right Grant
- 2010-02-09 JP JP2011549324A patent/JP5746638B2/ja not_active Expired - Fee Related
- 2010-02-09 EA EA201190110A patent/EA025085B1/ru not_active IP Right Cessation
- 2010-02-09 MX MX2014007180A patent/MX345562B/es unknown
- 2010-02-09 CA CA2751277A patent/CA2751277C/en not_active Expired - Fee Related
- 2010-09-02 UA UAA201110568A patent/UA110093C2/ru unknown
-
2011
- 2011-08-02 IL IL214396A patent/IL214396A/en not_active IP Right Cessation
- 2011-08-09 CL CL2011001906A patent/CL2011001906A1/es unknown
- 2011-08-26 CO CO11109501A patent/CO6420354A2/es active IP Right Grant
-
2014
- 2014-04-28 SM SM201400056T patent/SMT201400056B/xx unknown
- 2014-07-07 JP JP2014139374A patent/JP5951690B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-06 AU AU2015238785A patent/AU2015238785B2/en not_active Ceased
-
2017
- 2017-04-12 AU AU2017202413A patent/AU2017202413B2/en not_active Ceased
Non-Patent Citations (3)
| Title |
|---|
| Bioorganic & Medicinal Chemistry Vol. 15, PAges 5219-5229(공개일: 2007. 5. 22.)* |
| Collection Symposium Series, Vol. 10, Pages 347-349(공개일: 2008.) |
| J. Heterocyclic Chem. Vol. 30, Pages 509-515(공개일: 1999. Mar-Apr)* |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101834707B1 (ko) | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 | |
| KR101645742B1 (ko) | 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체 | |
| HK1163108B (en) | Carba-nucleoside analogs for antiviral treatment | |
| HK1154010B (en) | Carba-nucleoside analogs for antiviral treatment | |
| HK1152709B (en) | 1' -substituted carba-nucleoside analogs for antiviral treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
Fee payment year number: 1 St.27 status event code: A-2-2-U10-U12-oth-PR1002 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
Not in force date: 20210227 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE St.27 status event code: A-4-4-U10-U13-oth-PC1903 |
|
| PC1903 | Unpaid annual fee |
Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20210227 St.27 status event code: N-4-6-H10-H13-oth-PC1903 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |